Similar efficacy and safety of artemether-lumefantrine (Coartem?) in African infants and children with uncomplicated falciparum malaria across different body weight ranges
详细信息 查看全文
- 作者：Quique Bassat (1) (2)
Raquel González (1) (2)
Sónia Machevo (2)
Alain Nahum (3)
John Lyimo (4)
Hamma Maiga (5)
Andreas M?rtensson (6)
Mahfudh Bashraheil (7)
Peter Ouma (8)
David Ubben (9)
Verena Walter (10)
Obiyo Nwaiwu (11)
Chemtai Kipkeu (12)
Gilbert Lefèvre (10)
Bernhards Ogutu (13)
Clara Menéndez (1) (2) - 刊名：Malaria Journal
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：10
- 期：1
- 全文大小：259KB
- 参考文献：1. Trape JF: The public health impact of chloroquine resistance in Africa. / Am J Trop Med Hyg 2001,64(1- Suppl):12-7.
2. WHO: / Guidelines for the treatment of malaria. Second edition. World Health Organization web site. [Available at http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html Accessed March 29, 2010] World Health Organization web site. [Available at Accessed March 29, 2010]
3. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomized trial. / Lancet 2005, 365:1467-473. CrossRef
4. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, Mull R, Brockman A, White NJ, Nosten F: Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. / Trans R Soc Trop Med Hyg 2000, 94:545-48. CrossRef
5. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R: A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. / Am J Trop Med Hyg 2001, 64:247-56.
6. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P, De Palacios PI: Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. / Am J Trop Med Hyg 2006, 74:991-98.
7. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ: Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. / JAMA 2007, 297:2210-219. CrossRef
8. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI: Efficacy and safety of artemether-lumefantrine (Coartem ? ) tablets (six-dose regimen) in African infants and children with acute, uncomplicated malaria. / Trans R Soc Trop Med Hyg 2005, 99:459-67. CrossRef
9. Mutabingwa T, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. / Lancet 2005, 365:1474-480. CrossRef
10. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Bj?rkman A, M?rtensson A: Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children < 5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. / Clin Infect Dis 2011, 52:873-82. CrossRef
11. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, M?rtensson A: Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. / Malar J 2011, 10:64. CrossRef
12. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, Frühauf H, Schaub B, Pfeil J, Peshu J, Hanpithakpong W, Rippert A, Juma E, Tsofa B, Mosobo M, Lowe B, Osier F, Fegan G, Lindeg?rdh N, Nzila A, Peshu N, Mackinnon M, Marsh K: Declining responsiveness of plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. / PLoS One 2011, 6:e26005. CrossRef
13. Borrmann S, Sallas WM, Machevo S, González R, Bj?rkman A, M?rtensson A, Hamel M, Juma E, Peshu J, Ogutu B, Djimdé A, D'Alessandro U, Marrast AC, Lefèvre G, Kern SE: The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. / Trop Med Int Health 2010, 15:434-41.
14. Premji ZG, Abdulla S, Ogutu B, Ndong A, Falade CO, Sagara I, Mulure N, Nwaiwu O, Kokwaro G: The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. / Malar J 2008, 7:244. CrossRef
15. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. / Clin Pharmacokinet 1999, 37:105-25. CrossRef
16. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. / Expert Opin Pharmacother 2007, 8:75-4. CrossRef
17. White NJ: Antimalarial pharmacokinetics and treatment regimens. / Br J Clin Pharmacol 1992, 34:1-0.
18. Van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S: Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. / Am J Trop Med Hyg 1999, 60:936-42.
19. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, Genton B: Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. / Malaria J 2010, 9:48. CrossRef
20. Coartem ? /Riamet ? Basic Prescribing Information / Novartis Pharma AG Last updated September 2007
21. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, Hamel M, Ogutu B, M?rtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat Q, Juma E, Otieno L, Bj?rkman A, Beck HP, Andriano K, Cousin M, Lefèvre G, Ubben D, Premji Z: Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. / Lancet 2008, 372:1819-827. CrossRef
22. World Health Organization: Severe falciparum malaria. / Trans R Soc Trop Med Hyg 2000, 94:S1-S90. CrossRef
23. World Health Organization: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. [http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/] 2003.
24. Djimdé AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, Lefèvre G, Borrmann S: Pharmacokinetic and pharmacodynamic characteristics of artemether-lumefantrine dispersible tablet in African children with uncomplicated malaria. / Antimicrob Agents Chemother, in press.
25. Ashley EA, Stepniewska K, Lindeg?rdh N, McGready R, Annerberg A, Hutagalung R, Singtoroj T, Hla G, Brockman A, Proux S, Wilahphaingern J, Singhasivanon P, White NJ, Nosten F: Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. / Tropical Med Int Health 2007, 12:201-08. CrossRef
26. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Artemisinin Resistance in Cambodia 1 (ARC1) study consortium. Evidence of artemisinin-resistant malaria in western Cambodia. / N Engl J Med 2008, 359:2619-620. CrossRef
27. Rogier C, Ly AB, Tall A, Cissé B, Trape JF: Plasmodium falciparum clinical malaria in Dielmo, a holoendemic area in Senegal: no influence of acquired immunity on initial symptomatology and severity of malaria attacks. / Am J Trop Med Hyg 1999, 60:410-20.
28. Idro R, Bitarakwate E, Tumwesigire S, John CH: Clinical manifestations of severe malaria in the highlands of southwestern Uganda. / Am J Trop Med Hyg 2005, 72:561-67.
29. Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, Maiteki-Sebuguzi C, Clark TD, Nzarubara B, Njama-Meya D, Mpimbaza A, Rosenthal PJ, Kamya MR, Wabwire-Mangen F, Dorsey G, Talisuna AO: Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. / Malar J 2008, 7:107. CrossRef
30. Samba EM: The burden of malaria in Africa. / Afr Health 1997, 19:17. - 作者单位：Quique Bassat (1) (2)
Raquel González (1) (2)
Sónia Machevo (2)
Alain Nahum (3)
John Lyimo (4)
Hamma Maiga (5)
Andreas M?rtensson (6)
Mahfudh Bashraheil (7)
Peter Ouma (8)
David Ubben (9)
Verena Walter (10)
Obiyo Nwaiwu (11)
Chemtai Kipkeu (12)
Gilbert Lefèvre (10)
Bernhards Ogutu (13)
Clara Menéndez (1) (2)
1. Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Rosselló 132, 4°, 08036, Barcelona, Spain
2. Centro de Investiga??o em Saúde de Manhi?a (CISM), Manhi?a, Mozambique
3. Centre de Recherche Entomologique de Cotonou, Cotonou, Benin
4. Ifakara Health Research and Development Centre, Dar es Salaam, Tanzania
5. Malaria Research and Training Center, University of Bamako, Bamako, Mali
6. Division of Global Health, Dept of Public Health Sciences, Karolinska Institutet, Unit of Infectious Diseases, Dept of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Zanzibar Malaria Research Unit of the Karolinska Institutet, Zanzibar, Tanzania
7. Kenya Medical Research Institute, Kilifi, Kenya
8. Kenya Medical Research Institute, Center for Disease Control, Kisumu, Kenya
9. Medicines for Malaria Venture (MMV), Geneva, Switzerland
10. Novartis Pharma AG, Basel, Switzerland
11. Novartis Pharma AG, Mushin, Lagos, Nigeria
12. Novartis Pharma Services AG, Africa Re Centre, Hospital Road, Nairobi, Kenya
13. Walter Reed Project, Kenya Medical Research Institute, Kisumu, Kenya
文摘
Background Artemisinin-based combination therapy, including artemether-lumefantrine (AL), is currently recommended for the treatment of uncomplicated Plasmodium falciparum malaria. The objectives of the current analysis were to compare the efficacy and safety of AL across different body weight ranges in African children, and to examine the age and body weight relationship in this population. Methods Efficacy, safety and pharmacokinetic data from a randomized, investigator-blinded, multicentre trial of AL for treatment of acute uncomplicated P. falciparum malaria in infants and children in Africa were analysed according to body weight group. Results The trial included 899 patients (intent-to-treat population 886). The modified intent-to-treat (ITT) population (n = 812) comprised 143 children 5 to < 10 kg, 334 children 10 to < 15 kg, 277 children 15 to < 25 kg, and 58 children 25 to < 35 kg. The 28-day PCR cure rate, the primary endpoint, was comparable across all four body weight groups (97.2%, 98.9%, 97.8% and 98.3%, respectively). There were no clinically relevant differences in safety or tolerability between body weight groups. In the three AL body weight dosing groups (5 to < 15 kg, 15 to < 25 kg and 25 to < 35 kg), 80% of patients were aged 10-50 months, 46-100 months and 90-147 months, respectively. Conclusion Efficacy of AL in uncomplicated falciparum malaria is similar across body weight dosing groups as currently recommended in the label with no clinically relevant differences in safety or tolerability. AL dosing based on body weight remains advisable.